IMDZ Immune Design Corp.

6.45
+0  (3%)
Previous Close 6.25
Open 6.35
Price To book 1.67
Market Cap 164.08M
Shares 25,439,000
Volume 68,618
Short Ratio 7.46
Av. Daily Volume 79,045

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data at ASCO 2017 (June 5, 2017). Abstract 7537.
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2 data at ASCO 2017 (June 2, 2017). Abstract 11006.
CMB305
Soft tissue sarcomas

Latest News

  1. Immune Design Announces Presentations at the 2017 ASCO Annual Meeting
  2. ETFs with exposure to Immune Design Corp. : April 7, 2017
  3. Why Is Immune Design (IMDZ) Up 27.9% Since the Last Earnings Report?
  4. Immune Design Corp. :IMDZ-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  5. Immune Design Corp. :IMDZ-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  6. Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
  7. Immune Design reports 4Q loss
  8. Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  9. What's in Store for Immune Design (IMDZ) in Q4 Earnings?
  10. Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017
  11. Immune Design to Report Fourth Quarter and Year End 2016 Financial Results and Provide Corporate Update
  12. Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
  13. Immune Design to Present at Upcoming Investor Conferences
  14. ETFs with exposure to Immune Design Corp. : December 13, 2016
  15. Is Immune Design Corp (IMDZ) Going to Burn Investors?
  16. Immune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
  17. Here's Why Immune Design Should Be in Your Portfolio Now